Ginsenoside Rg1 nanoparticle penetrating the blood- brain barrier to improve the cerebral function of diabetic rats complicated with cerebral infarction

被引:49
作者
Shen, Junyi [1 ]
Zhao, Zhiming [1 ]
Shang, Wei [1 ]
Liu, Chunli [1 ]
Zhang, Beibei [1 ]
Zhao, Lingjie [1 ]
Cai, Hui [1 ]
机构
[1] Nanjing Univ, Sch Med, Jinling Hosp, Dept Integrated Tradit & Western Med, 305 East Zhong Shan Rd, Nanjing 210002, Jiangsu, Peoples R China
关键词
poly-gamma-glutamic acid; ginsenoside Rg1; OX26; blood-brain barrier; ENDOTHELIAL PROGENITOR CELLS; IN-VITRO; PROVIDES NEUROPROTECTION; VASCULAR COMPLICATIONS; ARTERY OCCLUSION; DELIVERY; QUANTIFICATION; DYSFUNCTION; TRIPTOLIDE; MIGRATION;
D O I
10.2147/IJN.S139602
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Diabetic cerebral infarction is with poorer prognosis and high rates of mortality. Ginsenoside Rg1 (Rg1) has a wide variety of therapeutic values for central nervous system (CNS) diseases for the neuron protective effects. However, the blood-brain barrier (BBB) restricts Rg1 in reaching the CNS. In this study, we investigated the therapeutic effects of Rg1 nanoparticle (PHRO, fabricated with gamma-PGA, L-PAE (H), Rg1, and OX26 antibody), targeting transferrin receptor, on the diabetes rats complicated with diabetic cerebral infarction in vitro and in vivo. Dynamic light scattering analysis shows the average particle size of PHRO was 79 +/- 18 nm and the polydispersity index =0.18. The transmission electron microscope images showed that all NPs were spherical in shape with diameters of 89 +/- 23 nm. PHRO released Rg1 with sustained release manner and could promote the migration of cerebrovascular endothelial cells and tube formation and even penetrated the BBB in vitro. PHRO could penetrate the BBB with high concentration in brain tissue to reduce the cerebral infarction volume and promote neuronal recovery in vivo. PHRO was promising to be a clinical treatment of diabetes mellitus with cerebral infarction.
引用
收藏
页码:6477 / 6486
页数:10
相关论文
共 36 条
[1]  
Abbott N Joan, 2004, Drug Discov Today Technol, V1, P407, DOI 10.1016/j.ddtec.2004.11.014
[2]   Preparation and characterization of biodegradable nanoparticles based on poly(γ-glutamic acid) with L-phenylalanine as a protein carrier [J].
Akagi, T ;
Kaneko, T ;
Kida, T ;
Akashi, M .
JOURNAL OF CONTROLLED RELEASE, 2005, 108 (2-3) :226-236
[3]  
ARFORS KE, 1979, ACTA PHYSIOL SCAND, P93
[4]   Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation [J].
Balestrieri, M. L. ;
Servillo, L. ;
Esposito, A. ;
D'Onofrio, N. ;
Giovane, A. ;
Casale, R. ;
Barbieri, M. ;
Paolisso, P. ;
Rizzo, M. R. ;
Paolisso, G. ;
Marfella, R. .
DIABETOLOGIA, 2013, 56 (01) :162-172
[5]   EVALUATION OF 2, 3, 5-TRIPHENYLTETRAZOLIUM CHLORIDE AS A STAIN FOR DETECTION AND QUANTIFICATION OF EXPERIMENTAL CEREBRAL INFARCTION IN RATS [J].
BEDERSON, JB ;
PITTS, LH ;
GERMANO, SM ;
NISHIMURA, MC ;
DAVIS, RL ;
BARTKOWSKI, HM .
STROKE, 1986, 17 (06) :1304-1308
[6]  
Begley DJ, 2003, PROG DRUG RES, V61, P39
[7]   DLS and zeta potential - What they are and what they are not? [J].
Bhattacharjee, Sourav .
JOURNAL OF CONTROLLED RELEASE, 2016, 235 :337-351
[8]   DIABETES AND STROKE [J].
BILLER, J ;
LOVE, BB .
MEDICAL CLINICS OF NORTH AMERICA, 1993, 77 (01) :95-110
[9]   Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies [J].
Calanna, S. ;
Christensen, M. ;
Holst, J. J. ;
Laferrere, B. ;
Gluud, L. L. ;
Vilsboll, T. ;
Knop, F. K. .
DIABETOLOGIA, 2013, 56 (05) :965-972
[10]   Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier [J].
Chang, Jiang ;
Jallouli, Youssef ;
Kroubi, Maya ;
Yuan, Xu-bo ;
Feng, Wei ;
Kang, Chun-sheng ;
Pu, Pei-yu ;
Betbeder, Didier .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 379 (02) :285-292